key: cord-0935689-1061vf13
authors: Valente-Acosta, B.; Hoyo-Ulloa, I.; Espinosa-Aguilar, L.; Mendoza-Aguilar, R.; Garcia-Guerrero, J.; Ontanon-Zurita, D.; Gomez-Gomez, B.; Fueyo-Rodriguez, O.; Vera-Zertuche, J. M.; Anzola-Arias, R.; Jimenez-Ceja, J. V.; Horta-Capinteyro, D.; Olvera-Guzman, C.; Aguirre-Sanchez, J.; Franco-Granillo, J.; Jauregui-Camargo, L.; Sada-Diaz, E.; Saavedra-Perez-Salas, R.; Palomar-Lever, A.; Moreno-Sanchez, F.
title: COVID-19 severe pneumonia in Mexico City - First experience in a Mexican hospital
date: 2020-05-01
journal: nan
DOI: 10.1101/2020.04.26.20080796
sha: a08fed4a6e6dfaba39248a185f6d5e37f5214adf
doc_id: 935689
cord_uid: 1061vf13

Background: Coronavirus Disease 2019 (Covid-19) pandemic since its first confirmed case, has changed the world. The need for accurate and truthful information is vital. Mexico and Latin America have been widely affected, so having local epidemiological data, will be of great clinical utility. Methods: A total of 33 hospitalized patients with Covid-19 pneumonia (either severe or critical) were identified from electronic health record in a third level care private hospital in Mexico City from March 13rd to April 13rd, 2020. We conducted a descriptive study of patients for characterization of the clinical, laboratory and radiologic findings, as well as complications. Results: The mean age was 60.6 (12.68) years and 23 (69.7%) were males. Twenty-three patients (69.6%) were overweight or obese. The median duration of symptoms before admission was 7 days. All the patients required mechanical invasive ventilation. The median duration of the mechanical ventilation was 12(2.6) days and all patients were extubated except one. All patients were started on antiviral treatment in the first 24 hours after admission once the diagnosis of Covid19 pneumonia was made. There was no difference between the treatment option and the length of stay. The extubation rate was higher (91.6%) than in other series, with no fatalities even though they were treated with different regimens. Conclusions: This one-centre experience describes the epidemiology, treatment and outcome of 33 patients with severe or critical COVID pneumonia admitted to the ICU. Most patients in our series were overweight or obese male, which we observed were of higher risk to present critical pneumonia, as well as high levels of Interleukin-6. The foregoing is relevant, due to the high incidence of these comorbidities in our country.

It is well known that since the first cases were identified in December 2019 in Wuhan, the capital of China's Hubei province, coronavirus disease 2019 (COVID-19) has changed not only medical practice but also the world itself. The virus that causes this disease has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) because of its resemblance to SARS-CoV: both belong to the coronavirus family. (1) As the pandemic evolves, having accurate local and international information has become vitally important. To the best of our knowledge, there are no published data on the clinical presentation and epidemiology of this disease in the Mexican population.

The flow of information from China, Europe and the United States could be used as a basis for our population; however, we must recognise that the Mexican population has very different social and health characteristics. (2) We present a retrospective case series from a tertiary-level private medical centre in Mexico City, which we believe is of great value, since it represents one of the first experiences in Latin America of the clinical behaviour of the virus.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org /10.1101 /10. /2020 We report a case series of patients with severe and critical COVID-19 pneumonia admitted to the American British Cowdray (ABC) Medical Center from 13 March to 13 April 2020. The ABC hospital is a tertiary-level care private hospital in Mexico City.

Thirty-three adults (≥ 18 years) were identified and divided into two groups (severe or critical pneumonia) depending on the pneumonia severity according to the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment.(3) Patients were classified in one of these groups depending on their presentation in the first 48 hours after admission. Pregnant women and children younger than 18 years of age were excluded from the study.

We obtained demographic, clinical, laboratory and radiologic data at admission and during the patients' hospitalisation from the electronic health record. The laboratory data and information on the treatment given were collected for all patients up to the time of the data cut, which occurred on 19 April 2020. Data were anonymised before analysis.

Informed consent was waived. The institutional ethics and research committee approved the protocol.

A confirmed case of COVID-19 was defined by a positive result on a reverse transcriptase-polymerase chain reaction (RT-PCR) assay of a specimen collected on a nasopharyngeal swab or a patient presenting with clinical and radiological signs . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 1, 2020. We divided patients into two groups: 1. Severe disease was defined as patients presenting with dyspnoea, a respiratory rate of more than 30/min, peripheral capillary oxygen saturation (SpO 2 ) of 90% breathing ambient air and/or a PaO 2 /Fio 2 ratio less than 231 (in agreement with the Mexico City altitude); 2. Critical disease was defined as severe pneumonia with respiratory failure requiring invasive mechanical ventilation, shock and/or other organ dysfunctions requiring admission to the intensive care unit (ICU).

Clinical specimens for SARS-CoV-2 diagnostic testing were obtained in accordance with the Center for Disease Control and Prevention guidelines. Different kits targeted the SARS-CoV-2 E-gene and the RdRP gene, including the RNeasy Mini Kit (Qiagen), and the LightCycler II Z480 (Roche®) with LightMix Modular detection system (TIB Molbiol, Roche) targeted the CoV E-gene, the CoV N-gene and the CoV RdRP gene.(4) Treatment was chosen at the attending physician's discretion. All the patients or patients' families gave their informed consent for the compassionate use of these drugs.

Afterwards, and only for analysis purposes, the patients were classified according to the medications received into the following groups:

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 1, 2020. . 1. Lopinavir/ritonavir (LPV/r) 400 mg/100 mg twice daily (BID) for 7 days + Interferon beta-1b (IFNb-1b) 0.25 mg every 48 h for 3 to 7 doses + Azithromycin (AZI) 500 mg initial dose and 250 mg daily for 5 days.

2. LPV/r 400 mg/100 mg (BID) for 7 days + IFNb-1b 0.25 mg every 48 h for 3 to 7 doses + AZI 500mg initial dose and then 250 mg daily for 5 days + Hydroxychloroquine (HCQ) loading dose of 400 mg BID and then 200 mg BID for 5 to 10 days.

3. LPV/r 400 mg/100 mg BID for 7 days + AZI 500 mg initial dose and then 250 mg daily 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 1, 2020. We used descriptive statistics expressed as numbers (percentages) for the categorical variables, and the continuous variables were expressed as mean ± standard deviation (SD) and median with interquartile range (IQR) values in accordance with their distribution. The Student's t-test or the Mann-Whitney test were performed to compare the differences between the continuous variables according to their distribution. The Kolmogorov-Smirnov test was used as evidence of normality. Significant differences between the categorical variables were evaluated using the Chi-square test. The ANOVA test was used to evaluate the differences between different treatment schemes and the length of stay. A p-value less than 0.05 was considered statistically significant.

All statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA).

We included all the patients managed by our infectious diseases team that were admitted to the intensive care COVID ward in the month following the first admission, which was on 12 March 2020. All the patients had severe or critical pneumonia. Patients were in the care of the intensive care and infectious diseases teams. The clinical characteristics of the patients at admission are depicted in Table 1 . We had 25 patients with severe pneumonia at admission and 8 patients with critical pneumonia that developed in the first 48 hours after admission.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. All patients were started on antiviral treatment in the first 24 hours after admission once the diagnosis of COVID-19 pneumonia was made. Four patients were treated with lopinavir/ritonavir and interferon beta-1b, and 9 patients were treated with this combination plus hydroxychloroquine. Nine patients were treated with lopinavir/r and hydroxychloroquine, and eleven patients were treated with only hydroxychloroquine. All . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. . the patients were on azithromycin. There was no difference between the treatment options and the length of stay. Tocilizumab was given to 17 (51.5%) patients: 6 (75%) patients in the CPG and 11 (44%) in the SPG, including 4 patients who progressed to critical pneumonia after 48 hours of admission. On average, patients received tocilizumab 3.3 ± 2.2 days after admission. Table 2 shows the laboratory and radiologic findings in the patients on admission to the hospital. All the patients had a complete blood count, a complete biochemistry panel and tests for D-dimer, ferritin, troponin I, C-reactive protein, procalcitonin and IL-6 levels. Ferritin, lactic dehydrogenase and IL-6 levels were significantly more elevated in critical pneumonia patients than in the severe pneumonia patients.

All the patients had bilateral infiltrates in the computed tomography scan (CT-scan).

Twelve (48%) patients with severe pneumonia had bilateral ground-glass infiltrates, while 6 (75%) patients with critical pneumonia had bilateral mixed infiltrates (alveolar occupation and ground-glass infiltrates).

Eight patients had critical pneumonia or developed it in the first 48 hours after admission. Four (16%) patients in the SPG developed critical pneumonia 48 hours after admission. All the critical patients required mechanical invasive ventilation. It is worth mentioning that we adhere to the Berlin definitions regarding the severity of respiratory . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.26.20080796 doi: medRxiv preprint failure, and if clinical situation required it, alternatives modalities of mechanical ventilation were implemented, including the prone position. The median duration of the mechanical ventilation was 12 ± 2.6 days. All the patients were extubated except one.

The patient who could not be extubated had previous Chronic obstructive pulmonary disease (COPD) and is now awake with a tracheostomy. Among the 12 patients who had critical pneumonia, 10 (83.3%) received tocilizumab.

We only documented two drug-related adverse reactions. One patient stopped lopinavir/ritonavir on the fifth day because of a considerable increase in bilirubin. After discontinuation, the bilirubin came down in 3 days. Another patient stopped azithromycin because of atrial fibrillation and a prolonged QT interval. Two patients developed subsegmental pulmonary emboli despite low-molecular-weight heparin thromboprophylaxis. Two patients required re-intubation, one because of lifethreatening abdominal bleeding that was treated by vascular surgery and another who . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.26.20080796 doi: medRxiv preprint developed complete right lung atelectasis. Both patients were able to be extubated in the next 72 hours after the bleeding and atelectasis resolved. Table 3 depicts the major outcomes of our cases. All patients were followed up until hospital discharge. The median follow-up day was 8 (IQR 5. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . For the 9 (27%) patients still in the hospital, we have at least 6 days of follow-up. As of 18 April 2020, none of the 33 patients has died. Twenty (80%) patients in the SPG and 4 (50%) patients in the CPG have been discharged. The median length of stay was 7.5 days (4.7-8.7) for the SPG and 23 days (16-24.7) for the CPG.

This single-centre experience describes the epidemiology, treatment and outcome of 33 patients with severe or critical COVID-19 pneumonia admitted to the ICU between 12

March and 13 April 2020.

Most patients in our case series were overweight or obese males with a chronic illness, most commonly hypertension or diabetes, similar to other reports.(1,5) Obesity and metabolic syndrome are chronic inflammatory diseases that make patients more prone to infectious complications and are known to have greater mortality in COVID-19 patients than patients with normal body mass index (BMI).(6) In our case series, all but one of the patients in the critical group were overweight or obese, and there was a trend towards higher BMI in the critical group compared to those in the severe group. The . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. in patients with obesity seems to be a chronic inflammatory and prothrombotic state, higher ACE2 concentrations in the alveolar epithelium plus a compromised pulmonary physiology.(9) Moreover, adipose tissue has been known to be a reservoir for some viruses, such as HIV and CMV; its role as a tissue reservoir in SARS-CoV-2 remains to be studied. (10) Fever and cough were the most common presenting symptoms, with a mean duration of 7 days before hospital admission. A higher respiratory rate and a lower PaO 2 / FiO 2 ratio at admission were significantly associated with the development of critical pneumonia.

These are two well-known markers of serious respiratory illness. (11) We found only two patients with influenza and one with a rhinovirus coinfection. Most of our patients were tested for other respiratory pathogens by molecular analysis. In contrast with other series that describe up to 20% of respiratory virus coinfection. (12) As described in Chinese and Italian reports, higher ferritin and lactic dehydrogenase levels at admission were also significantly associated with critical pneumonia. (13, 14) Moreover, we found that higher IL-6 concentration was significantly associated with . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.26.20080796 doi: medRxiv preprint critical pneumonia and the need for mechanical ventilation. This finding has previously been reported. (15, 16) All our patients were treated with different regimens of potential antiviral drugs against SARS-CoV2. The medication was started within 24 hours of admission. We could not compare the different schemes because our report is only a case series compared to well-designed trials. (17, 18) Tocilizumab was given to 11 (44%) and 6 (75%) of our severe and critical pneumonia patients, respectively. The rationale for such a decision was based on observational data implicating the overwhelming systemic inflammatory cascade as a culprit in the physiopathology of this new and poorly understood disease and the plausible role for immunomodulation in these populations. (19, 20) All the patients with critical COVID-19 pneumonia required mechanical ventilation with a mean duration of 12 days, similar to critically ill patients in Seattle, where the duration of mechanical ventilation was 10 days. (21) Noteworthy is that our extubation rate was higher (91.6%) than in other series. In addition, we did not have any fatalities.

Regarding complications, there were 3 cases of ventilator-associated pneumonia and only one with a multi-drug resistant bacterium, an extended spectrum beta-lactamase E.

coli. Secondary bacterial infection has been related to longer hospital stays and worse . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. . 7 (4-10) 6.5 (3.5-9.5) NS . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. .

LPV/r + IFNb-1b + AZI LPV/r + IFNb-1b +HCQ + AZI LPV/r + HCQ + AZI HCQ + AZI Tocilizumab in addition to previous treatment . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 1, 2020. . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 1, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 1, 2020. . https://doi.org/10.1101/2020.04.26.20080796 doi: medRxiv preprint

Clinical Characteristics of Coronavirus Disease 2019 in China

Severe Outcomes Among Patients with Coronavirus Disease

National Health Commission of the Peoples Republic of China. The diagnosis and treatment guide of COVID-19 pneumonia caused by new coronavirus infection

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill Bull Eur sur les Mal Transm = Eur Commun Dis Bull

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese J Tuberc Respir Dis

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Specific Biological Features of Adipose Tissue, and Their Impact on HIV Persistence

Clinical risks for development of the acute respiratory distress syndrome

Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Compassionate Use of Remdesivir for Patients with Severe Covid-19

COVID-19: consider cytokine storm syndromes and immunosuppression

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series